Table 1.
Characteristics of metastatic colorectal cancer patients with radical treatment (CRS-HIPEC, n = 180) or palliative/ explorative treatment (n = 77).
| Parameter | CRS-HIPEC (n = 180) | Palliative treatment (n = 77) | P | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Gender | 0.095 | ||||
| Female | 115 | 63.9 | 40 | 51.9 | |
| Male | 65 | 36.1 | 37 | 48.1 | |
| Age, median (year, range) | 59 | 22–77 | 58 | 20–72 | 0.313 |
| T-stage | <0.001 | ||||
| T1-2 | 1 | 0.6 | 2 | 2.9 | |
| T3 | 74 | 44.0 | 13 | 18.8 | |
| T4 | 93 | 55.4 | 54 | 78.3 | |
| Not reported | 12 | 8 | |||
| N-stage | 0.315 | ||||
| N0 | 51 | 28.7 | 17 | 24.3 | |
| N1 | 60 | 33.7 | 19 | 27.1 | |
| N2 | 67 | 37.6 | 34 | 48.6 | |
| Not reported | 2 | 0 | |||
| Number of metastatic lymph nodes, median (range) | 2 | 0–34 | 3 | 0–28 | 0.125 |
| Grade of tumour differentiation | 0.615 | ||||
| Poorly | 47 | 31.8 | 19 | 38.0 | |
| Moderate | 94 | 63.5 | 28 | 56.0 | |
| Well | 7 | 4.7 | 3 | 6.0 | |
| Not reported | 32 | 27 | |||
| Signet ring cells | 0.023 | ||||
| Present | 15 | 12.5 | 9 | 31.0 | |
| Absent | 105 | 87.5 | 20 | 69.0 | |
| Not reported | 60 | – | 48 | – | |
| Tumour location 1 | 0.017 | ||||
| Right colon | 76 | 42.2 | 45 | 58.4 | |
| Left colon and rectum | 104 | 57.8 | 32 | 41.6 | |
| Tumour location 2 | 0.367 | ||||
| Colon | 162 | 90.0 | 72 | 93.5 | |
| Rectum | 18 | 10.0 | 5 | 6.5 | |
| Peritoneal metastases | |||||
| Synchronous | 61 | 33.9 | 37 | 48.1 | 0.036 |
| Metachronous | 119 | 66.1 | 40 | 51.9 | |
| Chemoterapy earlier than CRS-HIPEC | 0.002 | ||||
| Yes | 124 | 68.9 | 40 | 51.9 | |
| No | 56 | 31.1 | 37 | 48.1 | |
| ASA | 0.011 | ||||
| 1 | 2 | 1.7 | 3 | 5.3 | |
| 2 | 108 | 92.3 | 43 | 75.4 | |
| 3 | 7 | 6.0 | 11 | 19.3 | |
| Not reported | 63 | 20 | |||
| CEA (median, range) (µg/L) | 4 | 1–1820 | 6 | 1–2562 | 0.224 |
| CA 19-9 (median, range) (U/L) | 18.5 | 5–1175 | 32 | 0–764 | 0.232 |
| PCI | <0.001 | ||||
| 0–10 | 111 | 61.7 | 6 | 7.8 | |
| 11–20 | 58 | 32.2 | 7 | 9.1 | |
| 21–30 | 10 | 5.6 | 37 | 48.1 | |
| >30 | 1 | 0.6 | 27 | 35.1 | |
| PCI, median (range) | 9 | 0–28 | 29 | 2-39 | <0.001 |
| Mutational status | 0.530 | ||||
| Double wt | 72 | 41.1 | 32 | 43.8 | |
| mutBRAF | 43 | 24.6 | 13 | 17.8 | |
| mutKRAS | 60 | 34.3 | 28 | 38.4 | |
| Missing | 5 | – | 4 | – | |
| BRAF | 0.430 | ||||
| mutBRAF with MSS | 29 | 16.8 | 13 | 17.8 | |
| mutBRAF with MSI | 12 | 6.9 | 2 | 2.7 | |
| wtBRAF | 132 | 76.3 | 58 | 79.5 | |
| Missing | 7 | – | 4 | – | |
| MSS/MSI | 0.849 | ||||
| MSS | 96 | 86.5 | 43 | 91.5 | |
| MSI | 15 | 13.5 | 4 | 8.5 | |
| Not analysed | 69 | – | 30 | – | |
| Complications | 0.064 | ||||
| Accordion 0–2 | 135 | 75.0 | 72 | 93.5 | |
| Accordion 3–6 | 45 | 25.0 | 5 | 6.5 | |
| Hospital stay (median days, range) | 10 | 5–57 | 7 | 2–24 | <0.001 |
| Operation time (median minutes, range) | 420 | 180–880 | 150 | 30–485 | <0.001 |
Statistically significant p < 0.05 values are in bold.